The Ki-67 status serves as a predictor for pathological complete response before neoadjuvant chemotherapy, being associated with high risk for metastasis or recurrence, poorer prognosis, and reduced survival, thus marking more aggressive forms of breast cancer [37, 38]. The gene discussed is MKI67; the disease is breast cancer.